Why “American Patients First” is likely to raise drug prices outside of the United States

Monique DabbousPublic Health Department, Aix-Marseille University, Marseille, FranceCorrespondence[email protected]

Cyprien MileaInternational Affairs, Sciences Po, Paris, France

https://orcid.org/0000-0002-3784-7200

Steven SimoensDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

Clement FrançoisPublic Health Department, Aix-Marseille University, Marseille, France

Claude DussartEA 4129 P2S (Parcours, Santé, Systémique), Lyon University, Lyon, France

Lylia ChachouaPublic Health Department, Market Access Society, Paris, France

Borislav BorissovPrescriptia, Sofia, Bulgaria

Mondher ToumiPublic Health Department, Aix-Marseille University, Marseille, France

https://orcid.org/0000-0001-7939-7204

show all

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Why “American Patients First” is likely to raise drug prices outside of the United States

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Why “American Patients First” is likely to raise drug prices outside of the United States

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date